Faculty Opinions recommendation of FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Keyword(s):
Phase 3
◽
Keyword(s):
Keyword(s):